AddLife AB Class B
0REZ.L
London Stock Exchange166.15
SEK
-4.85
- -
AddLife AB Class B
0REZ.L
(London Stock Exchange)
Recent
price
166.15
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- AddLife AB (publ) is a Swedish Medtech and Labtech company founded in 1906 and headquartered in Stockholm, Sweden, operating primarily in the European market. The company specializes in owning and acquiring niche market-leading subsidiaries that provide high-quality products, services, and advisory solutions to the healthcare and life sciences sectors. AddLife's operations are divided into two main business areas: Labtech and Medtech. The Labtech segment supplies products and solutions for diagnostics, biomedical research, and laboratory analysis, including diagnostic instruments, reagents, consumables, and laboratory equipment for areas such as haematology, pathology, cell biology, microbiology, molecular biology, clinical chemistry, immunology, and analytical instruments. This segment serves hospitals, research institutions, pharmaceutical companies, and the food industry, mainly in the Nordics and Europe. The Medtech business area offers medical device products and assistive equipment for publicly funded healthcare, homecare, and social care, including surgical products, respiration and intensive care devices, wound care, enteral nutrition, fall prevention, welfare technology, ENT products, and assistive devices for disabled children and bathroom/kitchen use across Europe. Recent major changes include the acquisition of Opitek International ApS, a Danish Medtech company specializing in patient positioning solutions that enhance staff ergonomics and patient safety during surgery, which now operates under AddLife’s Mediplast subsidiary. In 2023-2024, AddLife has pursued a strategic growth agenda characterized by multiple acquisitions contributing SEK 800 million in annual revenues, and has expanded its product portfolio by 25% with over 50 new product launches focused on advanced diagnostics and AI-driven medical technology solutions. The company’s latest financial results reflect strong organic growth with a 15% increase in revenue and a 228% profit improvement in recent quarters, driven by product portfolio shifts towards higher-margin offerings and efficiency initiatives. AddLife actively invests in research and development, allocating around 10% of revenue to R&D, and engages in collaborations with over 50 global partners to enhance innovation and supply chain capabilities. Environmentally, AddLife is committed to sustainability with a target of carbon neutrality by 2030, having reduced emissions by 20% in 2023. AddLife operates about 85 subsidiaries with roughly 2,300 employees across Sweden, Finland, Denmark, Norway, the UK, Ireland, Germany, Italy, Austria, Switzerland, and other European countries, serving a diverse range of public and private healthcare providers, research laboratories, and industrial clients. The company’s decentralized business model empowers its subsidiaries while leveraging group-wide strategic direction and financial strength to maintain its leading position in the Life Science sector. This comprehensive approach positions AddLife as a significant player in the European Medtech and Labtech markets, delivering advanced medical devices, laboratory equipment, and innovative healthcare solutions with continuous growth through acquisitions and product innovation.